BREAKING
Trican (TCW) Declares Dividend With 2025 Earnings But Withholds Key Performance Metrics 11 hours ago Trican Well Service Ltd (TCW) Reports Q4 2025 Earnings Results 11 hours ago Why Did FNF Stock Drop After Beating Earnings Estimates by Nearly 15%? 11 hours ago Fidelity National Financial, Inc (FNF) Tops Q4 2025 Earnings Estimates — EPS $1.63 vs $1.42 Expected 11 hours ago Rivian Stock (RIVN) Drops 5.2% as Investors Take Profits After 27% Post-Earnings Rally 13 hours ago Rivian Automotive, Inc. (RIVN) Drops 5.2% — Developing Story 13 hours ago Why Is ACN Stock Falling Today? Shares Plunge 21% Below Key Average Ahead of Earnings 13 hours ago Accenture plc (ACN) Drops 5.5% — Developing Story 13 hours ago BKNG Stock Plunges 7.65% to $3,925.75 Despite Beating Q4 Earnings Estimates 14 hours ago Booking Holdings Inc. (BKNG) Drops 7.7% — Developing Story 14 hours ago Trican (TCW) Declares Dividend With 2025 Earnings But Withholds Key Performance Metrics 11 hours ago Trican Well Service Ltd (TCW) Reports Q4 2025 Earnings Results 11 hours ago Why Did FNF Stock Drop After Beating Earnings Estimates by Nearly 15%? 11 hours ago Fidelity National Financial, Inc (FNF) Tops Q4 2025 Earnings Estimates — EPS $1.63 vs $1.42 Expected 11 hours ago Rivian Stock (RIVN) Drops 5.2% as Investors Take Profits After 27% Post-Earnings Rally 13 hours ago Rivian Automotive, Inc. (RIVN) Drops 5.2% — Developing Story 13 hours ago Why Is ACN Stock Falling Today? Shares Plunge 21% Below Key Average Ahead of Earnings 13 hours ago Accenture plc (ACN) Drops 5.5% — Developing Story 13 hours ago BKNG Stock Plunges 7.65% to $3,925.75 Despite Beating Q4 Earnings Estimates 14 hours ago Booking Holdings Inc. (BKNG) Drops 7.7% — Developing Story 14 hours ago
JNJ

Johnson & Johnson

$JNJ NYSE Jul 19, 2022 BMO Q2 2022

Investor Toolbox

Listen to Call

Watch or listen to the earnings call recording.

Open Webcast

Read Transcript

Transcript not yet available.

View Infographic

Visual summary of key financial data.

View Infographic

Earnings History

View past quarters and earnings trends.

View History

JNJ Coverage

Event Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer Feb 19, 2026 Event Johnson & Johnson (JNJ) Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania Feb 18, 2026 Event Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer Feb 18, 2026 Transcript Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript Jan 26, 2026 Transcript Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript Jan 22, 2026 News Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025 Jan 21, 2026 Research Johnson & Johnson: Healthcare Outlook Jan 20, 2026